Safety and Efficacy of Eliglustat with or without Imiglucerase in Pediatric Patients with Gaucher Disease (GD) Type 1 and Type 3 (ELIKIDS)

Trial Identifier: EFC13738
Sponsor: Sanofi
Start Date: April 2018
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Gaucher Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
ARGENTINA, Buenos Aires Buenos Aires, ARGENTINA, 1428
Canada, Ontario Toronto, Ontario, Canada, M5G 1X8
CANADA, Alberta Calgary, Alberta, CANADA, T3B 6A9
CANADA, British Columbia Vancouver, British Columbia, CANADA, V6H 3N1
FRANCE Bron, FRANCE, 69500
ITALY, Roma Rome, Roma, ITALY, 00165
JAPAN, Saitama Koshigaya, Saitama, JAPAN, 343-0845
JAPAN, Tokyo Tokyo, JAPAN, 105-8461
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 119049
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 119991
RUSSIAN FEDERATION Saint Petersburg, RUSSIAN FEDERATION, 197341
RUSSIAN FEDERATION Tomsk, RUSSIAN FEDERATION, 634050
SPAIN, Barcelona [Barcelona] Esplugues De Llobregat, Barcelona [Barcelona], SPAIN, 08950
SPAIN, Pais Vasco Barakaldo, Pais Vasco, SPAIN, 48903
SPAIN, Zaragoza Zaragoza, SPAIN, 50012
SWEDEN Gothenburg, SWEDEN, 416 85
SWEDEN Luleå, SWEDEN, 971 80
Turkey Adana, Turkey, 01300
Turkey Istanbul, Turkey, 34093
Turkey Izmir, Turkey, 35040
UNITED KINGDOM, England Birmingham, England, UNITED KINGDOM, B4 6NH